Affymetrix, Inc. v. Synteni, Inc.

28 F. Supp. 2d 192, 1998 U.S. Dist. LEXIS 18849, 1998 WL 839942
CourtDistrict Court, D. Delaware
DecidedNovember 18, 1998
DocketCIV. A. 98-006-GMS, 98-520-GMS
StatusPublished
Cited by85 cases

This text of 28 F. Supp. 2d 192 (Affymetrix, Inc. v. Synteni, Inc.) is published on Counsel Stack Legal Research, covering District Court, D. Delaware primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Affymetrix, Inc. v. Synteni, Inc., 28 F. Supp. 2d 192, 1998 U.S. Dist. LEXIS 18849, 1998 WL 839942 (D. Del. 1998).

Opinion

OPINION

SLEET, District Judge.

I. INTRODUCTION.

Plaintiff, Affymetrix, Inc. (“Affymetrix”), has filed two actions for patent infringement against Defendants Synteni, Inc. (“Synteni”) and Incyte Pharmaceuticals, Inc. (“Incyte”) with this Court.

On January 6, 1998, Affymetrix filed the first of these two lawsuits, Civil Action No. 98-6, alleging the willful infringement of U.S. Patent No. 5,445,934 (“the ’934 patent”) by Synteni and Incyte. Eight months later, on September 1, 1998, Affymetrix filed a second lawsuit, Civil Action No. 98-520, for the alleged infringement of U.S. Patent Nos. 5,744,305 (“the ’305 patent”) and 5,800,992 (“the ’992 patent”). Both complaints seek injunctive relief as well as money damages.

This Court has jurisdiction pursuant to 35 U.S.C. §§ 101, et seq. and 28 U.S.C. §§ 1331 and 1338.

In both instances, before answering, Syn-teni and Incyte moved under 28 U.S.C. § 1404(a) to transfer these actions from the District of Delaware to the Northern District of California. For the reasons discussed below, the Court grants both of these motions.

II. THE PARTIES AND THEIR INVENTIONS.

Affymetrix, a wholly-owned subsidiary of Affymax N.V. (“Affymax”), first began operating in the early 1990s to pursue research in the field of high density arrays. These arrays contain thousands of sequences of genetic material and are used by medical and scientific researchers in their search to discover the causes of (and cures for) diseases such as cancer and AIDS.

In developing this technology, Affymetrix has obtained a number of patents. Those in suit are the ’934, ’305, and ’992 patents. These patents describe the process that Aff-ymetrix uses in manufacturing its high density arrays which are sold under the trademark “GeneChip.”

At the same time that Affymetrix was conducting its research into high density arrays, Incyte broke ground on its own development — the creation of a portfolio of “genomic” databases which catalogued millions (if not billions) of series of genetic information. These databases were (and still are) used by the research and development divisions of major pharmaceutical companies to not only perfect existing drugs but also create new ones.

In 1996, Affymetrix and Incyte joined forces to develop a set of customized high density arrays, sold under the trademark “LifeChips.” However, in January of 1998, Incyte acquired Synteni and began to market its own competing (the accused) product— *194 the Gene Expression Micro-Array (or “GEM”).

At the time, Synteni was a privately-held company. Originally incorporated under California law in 1994, Synteni reincorporated under Delaware law in 1997 (one year before it was acquired by Incyte). Presently, Synteni holds the exclusive world-wide rights from Stanford University (“Stanford”) to commercialize the GEM array technology. The GEM array is a “high density array of DNA molecules bonded onto a small glass surface.” Synteni markets the GEM array to companies in the agricultural and pharmaceutical industries.

Shortly after Incyte acquired Synteni, Aff-ymetrix filed these two lawsuits.

III. THE RELEVANT FACTS.

At the time that both of these actions were filed, Affymetrix was a California corporation with its principal place of business in Santa Clara, California. 1 Synteni and Incyte, on the other hand, were (and, in fact, still are) Delaware corporations 2 with their principal places of business in the respective cities of Fremont and Palo Alto, California.

A. Their Connection (Or Lack Thereof) To The District of Delaware.

None of the parties maintain any facilities or employ any personnel in Delaware. They manufacture none of their products (accused or otherwise) and conduct none of their research or development here. Moreover, they maintain no warehouses or other storage facilities in Delaware. Additionally, they store no relevant files, records, or other documents in the District. Finally, none of'them keeps any mail drops, bank accounts, or telephone numbers in Delaware.

B. Their Connection To The Northern District Of California.

The headquarters and laboratories of all of three of these companies are located within roughly twenty miles of each other in the area of northern California known as Silicon Valley. Synteni and Incyte maintain all of their research laboratories, sequencing facilities, and administrative buildings in either Fremont or Palo Alto. All of their employees reside in California, and all of their records are kept there. Affymetrix maintains all of its corporate offices and research facilities in Santa Clara. All of its employees and records are located in California as well. Thus, the overwhelming majority of the witnesses whom the parties intend to call at trial as well as all of the relevant documents (including numerous laboratory notebooks) are located in the Northern District of California.

*195 1. The inventors.

Five of the six inventors named in the patents in suit reside in the Northern District. While the sixth permanently resides in North Carolina, for the next eight months (or so) he will be living in southern California.

Specifically, three of the four inventors listed on the ’934 and ’305 patents (Stephen Fodor, Leighton Read, and Lubert Stryer) reside in the Northern District of California. The fourth (Michael Pirrhng) is a professor at Duke University and resides in North Carolina. He, however, is currently on sabbatical, teaching at the University of California in San Diego. He thus lives approximately 500 miles South of the Northern District. Of the remaining two inventors 3 listed on’992 patent (Denis Solas, and William Dower), both reside in the Northern District.

Dr. Fodor is the Chief Executive Officer of Affymetrix and, therefore, a party witness. In their affidavits, Dr. Read and Professor Stryer have pledged that they will make themselves available for trial. They only ask sufficient notice in order to make proper arrangements with respect to their teaching and research obligations. Finally, in both of their declarations, Mr. Solas and Mr. Dower aver their willingness to voluntarily attend trial if needed.

2. Other witnesses.

In addition to these six inventors, Synteni and Ineyte expect to call Patrick Brown, Dari Shalon, Ron Davis, Mark Schena, and Radjoe Drmanac at trial.

Professor Brown is a member of the Stanford faculty who conducts research into micro-array technology.

Dr.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
28 F. Supp. 2d 192, 1998 U.S. Dist. LEXIS 18849, 1998 WL 839942, Counsel Stack Legal Research, https://law.counselstack.com/opinion/affymetrix-inc-v-synteni-inc-ded-1998.